Fresenius Medical Care Issues Class 4 Medicines Defect Notification for Peritoneal Dialysis Solution

Fresenius Medical Care Deutschland GmbH has issued a Class 4 Medicines Defect Notification concerning its balance solution containing 2.3% glucose and 1.25 mmol/l calcium, intended for peritoneal dialysis. The notification highlights a critical error in the Braille printed on the outer label, which may lead to misinterpretation of the product’s usage instructions.

This defect is particularly concerning as accurate labeling is essential for patient safety, especially in a setting where precise dosing and administration are crucial. The Braille error could potentially result in improper use of the product, thereby impacting patient outcomes and compliance with regulatory standards.

As a response, stakeholders in the pharmaceutical sector, including regulatory affairs, quality assurance, and supply chain management, must ensure that such labeling issues are promptly addressed. This incident underscores the importance of rigorous quality control measures in the manufacturing process to prevent similar occurrences in the future.